Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 12/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315551 | 0.81 | ENPP2 (0.48) | ULK1ENPP2ATXN2PDPK1POLB | |
| SCHEMBL3734462 | 0.73 | SMN1; SMN2 (0.46) | L3MBTL1 | |
| SCHEMBL18315523 | 0.72 | ENPP2 (0.49) | ULK1ENPP2ATXN2PDPK1POLB | |
| SCHEMBL142543 | 0.72 | ULK1 (0.56) | ULK1PDPK1POLBL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL16616200 | 0.69 | ENPP2 (0.40) | ENPP2ATXN2SMYD3L3MBTL1 | |
| SCHEMBL1156215 | 0.69 | PEPD (0.42) | PDPK1 | |
| Trifluoroacetic Acid SCHEMBL27736713 | 0.67 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL1247686 | 0.66 | ROCK2 (0.55) | POLBMAOAMAOB | |
| SCHEMBL6519579 | 0.66 | TERT (0.48) | — | |
| SCHEMBL9172845 | 0.65 | ROCK2 (0.54) | POLBMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9493486-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHES INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | ULK1 160/4885ENPP2 1/4885ATXN2 280/4885 |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | ENPP2, DAPK1, DAPK2 | ULK1 206/4885ENPP2 1/4885ATXN2 500/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | ULK1 307/4885ENPP2 548/4885ATXN2 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.